Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-101 DDI with Nintedanib in Healthy Subjects
NCT05817240Phase 1Completed
- Sponsor
- Endeavor BioMedicines
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taladegib in idiopathic pulmonary fibrosis (IPF), sponsored by Endeavor BioMedicines. Primary endpoints: Nintedanib maximum blood concentration at Day 7, Time of nintedanib maximum blood concentration at Day 7 and 3 more. Started May 2023; status: completed.
02
Drugs
taladegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05817240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817240.